Aptevo Therapeutics Presents Data on Its ADAPTIR™ Antibody Platform at the 16th Annual PEPTALK Conference
January 12 2017 - 8:02AM
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company
focused on developing novel oncology and hematology therapeutics,
today announced that Dr. John Blankenship, a Lead Scientist at
Aptevo, presented new data on the Company’s bispecific antibody
program based on the ADAPTIR platform technology at the 16th Annual
PEPTALK conference in San Diego, January 9-13, 2017.
In a presentation entitled “ADAPTIR™ Platform, a
Novel Platform for Development of Immuno-Oncology Therapeutics,”
Dr. Blankenship presented new in vivo, in vitro, pharmacokinetic
(PK) and stability data highlighting the advantages of using the
ADAPTIR platform to develop novel immuno-oncology
therapeutics.
“The field of bispecific therapeutics is a
rapidly emerging area in biotechnology and parallels the
development of monoclonal antibodies many decades ago, but with
greater therapeutic promise," said Dr. Jane Gross, Senior Vice
President and Chief Scientific Officer for Aptevo. “The
ability to engage the immune system to fight cancer and other
chronic diseases is a concept that has been heralded for some time,
yet recent technological and scientific advances have made the
promise of immunotherapy more achievable.
As pioneers in this field, Aptevo has developed
the ADAPTIR platform to engage the immune system in a targeted,
controlled fashion. Data presented at the conference showed that
ADAPTIR molecules offer key advantages over other bispecific
formats, derived in part from the flexible and modular nature of
the ADAPTIR structure. Potent biological activity can be achieved,
while retaining standard manufacturing characteristics.
ADAPTIR bispecific molecules utilize a homodimeric format that
avoids the potential manufacturing issues associated with
heterodimeric bispecific formats. In addition, ADAPTIR
bispecific molecules have demonstrated antibody-like serum
half-life in rodents (up to 12 days in mice), in the data presented
at PEPTALK.”
Data were also presented showing that ADAPTIR
molecules have unique properties for redirecting T-cell
cytotoxicity (RTCC) compared to other bispecific platforms,
including a favorable cytokine release profile. Preclinical
studies presented by Dr. Blankenship at PEPTALK and recently
published in the Journal of Molecular and Cellular Biology (2016
Mol Cancer Ther; 15(9); 2155–65.) demonstrated the increased
potency of ADAPTIR molecules, which displayed target-dependent
induction of RTCC at lower concentrations than other bispecific
antibody formats. In addition, in these studies, ADAPTIR
molecules were shown to induce T-cell proliferation and serial
lysis of target-bearing cells, but with lower levels of T-cell
dependent cytokines compared to other bispecific formats. If
these data are confirmed in clinical studies, it could suggest the
potential for enhanced safety and tolerability compared to other
immuno-oncology approaches.
Two ADAPTIR molecules are currently undergoing
clinical trials, with several more bispecific immunotherapies in
preclinical development. The advantages of the ADAPTIR platform
provides an opportunity for diverse therapeutic applications in the
future.
About Aptevo Therapeutics Inc.Aptevo
Therapeutics Inc. is a biotechnology company focused on novel
oncology and hematology therapeutics to meaningfully improve
patients’ lives. Our core technology is the ADAPTIR™ modular
protein technology platform. Aptevo has four commercial products in
the areas of hematology and infectious diseases, as well as various
investigational stage product candidates in immuno-oncology.
Safe Harbor StatementThis press
release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including,
without limitation, statements regarding Aptevo’s outlook,
financial performance or financial condition, our technology and
related pipeline, collaboration and partnership opportunities,
commercial portfolio and any other statements containing the words
“believes,” “expects,” “anticipates,” “intends,” “plans,”
“forecasts,” “estimates,” “will” and similar expressions are
forward-looking statements. These forward-looking statements are
based on Aptevo’s current intentions, beliefs and expectations
regarding future events. Aptevo cannot guarantee that any
forward-looking statement will be accurate. Investors should
realize that if underlying assumptions prove inaccurate or unknown
risks or uncertainties materialize, actual results could differ
materially from Aptevo’s expectations. Investors are, therefore,
cautioned not to place undue reliance on any forward-looking
statement. Any forward-looking statement speaks only as of the date
of this press release, and, except as required by law, Aptevo does
not undertake to update any forward-looking statement to reflect
new information, events or circumstances.
There are a number of important factors that
could cause our actual results to differ materially from those
indicated by such forward-looking statements, including possible
negative effects on our business operations, assets or financial
results as a result of the separation; a deterioration in our
business or prospects; the ability of our contractors and suppliers
to supply product and materials; our ability and the ability
if our contractors and suppliers to maintain compliance with cGMP
and other regulatory obligations; the results of regulatory
inspections; adverse developments in our customer-base or markets;
adverse developments in the U.S. or global capital markets, credit
markets or economies generally; and changes in regulatory, social
and political conditions. Additional risks and factors that may
affect results are set forth in our filings with the Securities and
Exchange Commission, including Aptevo’s most recent Quarterly
Report on Form 10-Q, as filed on November 14, 2016. The foregoing
sets forth many, but not all, of the factors that could cause
actual results to differ from our expectations in any
forward-looking statement.
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Apr 2024 to May 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From May 2023 to May 2024